When is it too late to start PARP manitenance after adjuvant chemotherapy in BRCA mutated ovarian cancer who had a delay in completing genetic testing?

Niraparib's prescribing information specifies that in the first-line maintenance setting, patients should start treatment no later than 12 weeks after their most recent platinum-containing regimen. In the setting of maintenance after recurrent ovarian cancer, treatment should start no later than 8 weeks after the most recent platinum-containing regimen.

Rucaparib's FDA approved indication maintenance specifies that treatment is for patients with recurrent disease who are in "complete or partial response to platinum-based" therapy". No time window is specified.

Olaparib has similar indications for maintenance in women after front-line treatment and recurrent disease "who are in complete or partial response to platinum-based therapy" without ...